کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6094567 | 1209808 | 2014 | 17 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
HTAInterferon-free regimenssimeprevirSofosbuvirRdRpDAASVRDirect-acting antiviral - اقدام ضد ویروسی مستقیمinterferon - اینترفرونIFN - اینترفرون هاdirect-acting antivirals - داروهای ضد ویروسی مستقیمdaclatasvir - داکلاتاشیرHepatitis C virus - هپاتیت سیHCV - هپاتیت سیhuman immunodeficiency virus - ویروس نقص ایمنی انسانیHIV - ویروس نقص ایمنی انسانی Sustained virologic response - پاسخ پایدار ویروسی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای گوارشی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges](/preview/png/6094567.png)
چکیده انگلیسی
Therapy for hepatitis C is undergoing a revolution. Several new drugs against the hepatitis C virus (HCV) have reached the market and many others, including direct-acting antivirals and host-targeted agents, are in phase II or III clinical development. All-oral, interferon-free combinations of drugs are expected to cure more than 90% of infections. A vast amount of data from clinical trials are presented regularly at international conferences or released to the press before peer-review, creating confusion in the viral hepatitis field. The goal of this review is to clarify the current stage of HCV therapy and drug development. This review describes the different classes of drugs and their mechanisms and properties, as well as treatment strategies in development, including those that are interferon-based and interferon-free. HCV treatment options that will be available in 2014-2015 are presented for each genotype. A number of unanswered questions and challenges remain, such as how to treat special populations, the role of ribavirin in interferon-free regimens, the role of HCV resistance in treatment failures, and how to best re-treat patients who failed on treatment. Strategic choices, cost issues, HCV screening, and improving access to care in resource-constrained areas also are discussed.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gastroenterology - Volume 146, Issue 5, May 2014, Pages 1176-1192
Journal: Gastroenterology - Volume 146, Issue 5, May 2014, Pages 1176-1192
نویسندگان
Jean-Michel Pawlotsky,